An integrated interdisciplinary approach to animal-free nanomaterial and chemical safety assessment.

::home:::      ::news::      ::background::      ::projects::      ::work plan::      ::training::      .:ESTIV:.
The in3 project is funded by the EU's Marie Skłodowska-Curie Action - Innovative Training Network (MSCA-ITN for short)  that aims to drive the synergistic development and utilisation of in vitro and in silico tools for human chemical and nanomaterial (NM) safety assessment. The project will focus on differentiation of human induced Pluripotent Stem Cells (hiPSC) to toxicologically relevant target tissues including; brain, lung, liver and kidney. The tissues, from the same genetic backgrounds, will be exposed to several compounds and the data generated will be used to develop safety assessment approaches by integrating cheminformatics, mechanistic toxicology and biokinetics into computational models. The project will hire 15 PhD students to carry out these activities in a coordinated and highly collaborative fashion.  The scientists trained within in3 will acquire a unique multidisciplinary skill set giving them a competitive employment advantage in safety assessment sciences either in industry, governmental bodies or academia.

Core scientific activities:
  • Differentiation of well-characterised human iPSC into brain, lung, liver, kidney and vascular cells
  • Delineation of tissue specific and donor specific effects of compound exposures (uptake, metabolism, extrusion, and mechanistic toxicity)
  • Development and optimisation of quantitative adverse outcome pathways (qAOPs) for each target organ which will be unified in an organism-level model
  • Optimisation of QSAR and read-across tools for safety assessment
  • Ultimately to create a  unified expandable integrated testing strategy for chemical and NM safety assessment

  • For individual projects   click here.

    in3 Consortium Beneficiaries (Hosts) and Partner Organisations

    Vrjie Universiteit Amsterdam, Molecular and Computational Toxicology,  Prof. Dr. Paul Jennings. Coordinator.
    Evercyte GmbH, Austria. Assoc. Prof. Regina Grillari
    Université d’Artois, France. BBB Laboratory. Assoc. Prof. Maxime Culot
    University of Lausanne, Switzerland. Physiology. Marie-Gabrielle Zurich
    BIOTALENTUM, Hungary. Prof. Andras Dinnyes
    University of Leuven, Leuven, Belgium.  KU Leuven Stem Cell Institute,  Prof. Catherine Verfaillie
    Department of Health – Public Health England, United Kingdom. Toxicology Dept./Centre for Radiation, Chemical and Environmental Hazards/Nanotoxicology Laboratory. Dr. Martin Leonard.
    Newcells Biotech, United Kingdom. Prof. Lyle Armstrong
    Instituto di Ricerche Farmacologiche Mario Negri, Italy. Environmental Health Sciences/Laboratory of Environmental Chemistry and Toxicology. Prof. Emilio Benfenati
    Liverpool John Moores University, United Kingdom. School of Pharmacy and Biomolecular Sciences. Prof. Mark Cronin
    National Institute of Chemistry, Ljubljana, Slovenia. Laboratory of Chemometrics. Prof. Marjana Novič
    Universiteit Utrecht, The Netherlands. Institute for Risk Assessment Sciences/Toxicology. Ass. Prof. Nynke Kramer
    Douglas Connect, Switerland. Dr. Barry Hardy

    Partner Organisations
    Center for Alternatives to Animal Testing – EUROPE, Universität Konstanz, Germany. Dr. Mardas Daneshian
    European Union Reference Laboratory for alternatives to animal testing, Italy. Institute for Health and Consumer Protection, European Commission Joint Research Centre. Dr. Anna Price
    European Society of Toxicology in vitro, The Netherlands.Assoc. Prof. Mathieu Vinken
    Nanocomposix Europe, Czech Republic. Karolina Sauerova
    L’Oreal, France. Gladys Ouedraogo

    in3 is funded by the Marie Skłodowska-Curie Action - Innovative Training Network under grant no. 721975.